Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Fineline Cube Dec 22, 2025
Company Drug

Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT

Fineline Cube Dec 22, 2025
Company Drug

Lion TCR Enrolls First Patient in LioCyx-M004 Study for HBV-Related Liver Cancer

Fineline Cube Aug 2, 2022

Singapore-based clinical-stage biotech Lion TCR announced the enrollment of the first subject in a clinical...

Company Drug

Grand Pharma’s TLX591-CDx and TLX250-CDx Advance in China with NMPA Review

Fineline Cube Aug 2, 2022

Grand Pharmaceutical Group Limited (HKG: 0512) announced that the National Medical Products Administration (NMPA) has...

Company Deals

OriginCell Therapeutics Raises USD 120M in Series B for Tumor Immunotherapy Pipeline

Fineline Cube Aug 1, 2022

OriginCell Therapeutics, a Shanghai-based tumor immunotherapy specialist, reportedly raised over USD 120 million in a...

Company Deals

Fosun Pharma to Hike Aitrox Stake to 72.63% for USD 61M

Fineline Cube Aug 1, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) plans to increase its ownership...

Company Deals

GluBio Pharma Raises USD 22M in Series A+ Round to Advance TPD Pipeline

Fineline Cube Aug 1, 2022

GluBio Pharmaceutical Co., Ltd, a Zhejiang-based specialist in molecular glue targeted protein degradation (TPD), reportedly...

Company Deals

Ribo Life Science Raises USD 40M in Series E1 Round for siRNA Drug Development

Fineline Cube Aug 1, 2022

China-based Suzhou Ribo Life Science Co., Ltd reportedly raised USD 40 million in a Series...

Company Deals

BridGene Biosciences Completes USD 38.5M Series B Round with China Funds

Fineline Cube Aug 1, 2022

U.S.-based biotech BridGene Biosciences Inc. has completed a Series B financing round, raising USD 38.5...

Company Deals Hospital

Basecare Medical Sells 35% Stake in Cellpro Biotech for USD 9.5M

Fineline Cube Aug 1, 2022

Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based IVF specialist, will sell a 35%...

Company Drug

Sanjin Pharma’s Subsidiary Gets FDA Nod for BC007 Cancer Drug Trial

Fineline Cube Aug 1, 2022

China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Pharmaceutical...

Company Deals Digital

Pica Partners with BrainCo to Launch ADHD Product in China

Fineline Cube Aug 1, 2022

Shanghai-based primary healthcare digital platform Pica, developed by Wuxi AppTec in 2016, has partnered with...

Hospital Policy / Regulatory

NHC Designates National Mental Illness Medical Centers in Beijing and Shanghai

Fineline Cube Aug 1, 2022

The National Healthcare Commission (NHC) announced the establishment of national mental illness medical centers, designating...

Company Drug

Innovent and Laekna Dose First Patient in Afuresertib and Tyvyt Study for PD-1 Resistant Tumors

Fineline Cube Aug 1, 2022

China’s Innovent Biologics Inc. (HKG: 1801) and partner Laekna Therapeutics Shanghai Co., Ltd announced that...

Company Drug

Dongcheng Pharmaceutical Gets NMPA Green Light for PSMA PET Imaging Drug

Fineline Cube Aug 1, 2022

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced it has received approval from...

Company Drug

CanSino Biologics Launches Menhycia Meningococcal Vaccine in Six Provinces

Fineline Cube Aug 1, 2022

China-based CanSino Biologics (HKG: 6185) announced the launch of its ACYW135 Meningococcal Conjugate Vaccine (CRM197)...

Company Drug

Mabwell Bioscience Gets FDA Approval for Nectin-4 ADC 9MW2821 in Solid Tumors

Fineline Cube Aug 1, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced it has received approval from the...

Company Drug

LaNova Medicines Gets FDA Green Light for LM-305 Myeloma Study

Fineline Cube Aug 1, 2022

Shanghai-based cancer therapy developer LaNova Medicines Ltd announced it has received approval from the U.S....

Company

Sanofi’s Q2 Earnings Show 8.1% Global Sales Growth, Led by Dupixent and China Expansion

Fineline Cube Jul 29, 2022

France-based Sanofi (NASDAQ: SNY) reported Q2 2022 global sales of EUR 10.1 billion (USD 10.3...

Company Drug

CSPC Pharmaceutical’s Albumin-Bound Docetaxel Receives Orphan Drug Designation for Gastric Cancer

Fineline Cube Jul 29, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received an orphan drug...

Drug

Hybio Pharmaceutical’s Liraglutide Filing Accepted by NMPA, Becomes Domestic Leader in GLP-1 Analog

Fineline Cube Jul 29, 2022

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its market filing for liraglutide, a...

Drug

Roche’s Rozlytrek Wins NMPA Approval for NTRK Fusion Gene-Positive Tumors

Fineline Cube Jul 29, 2022

Swiss pharmaceutical giant Roche announced that it has received marketing approval from the National Medical...

Posts pagination

1 … 577 578 579 … 600

Recent updates

  • Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis
  • MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED
  • Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal
  • Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT
  • GSK’s Nucala Wins China Approval as First IL‑5 Biologic for COPD
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Company Drug

Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.